R
Robert M. DiPardo
Researcher at United States Military Academy
Publications - 61
Citations - 3403
Robert M. DiPardo is an academic researcher from United States Military Academy. The author has contributed to research in topics: Cholecystokinin & Receptor. The author has an hindex of 21, co-authored 61 publications receiving 3268 citations. Previous affiliations of Robert M. DiPardo include Merck & Co..
Papers
More filters
Journal ArticleDOI
Application of the thioimidate cyclopropane rearrangement to heterocyclic synthesis. Preparation of diaryl pyrrolines
TL;DR: Substituent effects on the thioimidate cyclopropane rearrangement and factors affecting regioselectivity are reported in this paper, where Palladium-mediated coupling of the pyrrolothiomethylimidate rearrangements products with Grignard reagents provides diary l pyrrlines in good yields.
Journal ArticleDOI
Benzolactams as non-peptide cholecystokinin receptor ligands
Mark G. Bock,Robert M. DiPardo,D. F. Veber,Raymond S.L. Chang,Victor J. Lotti,Stephen B. Freedman,Roger M. Freidinger +6 more
TL;DR: A series of 1,3-substituted benzolactams are reported which are nonpeptidal receptor ligands of the peptide hormone cholecystokinin (CCK) which have been demonstrated to enhance the affinity of certain 1,4-benzodiazepine CCK-A antagonists for theCCK-B receptor.
Journal ArticleDOI
A second generation of non-peptide cholecystokinin receptor antagonists and their possible therapeutic potential.
Stephen B. Freedman,S. Patel,Alison J. Smith,Kerry L. Chapman,Alan E. Fletcher,John A. Kemp,George R. Marshall,Richard Hargreaves,Kate Scholey,E. C. Mellin,Robert M. DiPardo,Mark G. Bock,Roger M. Freidinger +12 more
TL;DR: A second generation of CCK-B receptor antagonists such as L-368,935 will be important in determining the therapeutic potential of this class of compound in man.
Journal ArticleDOI
Curtius rearrangement in the 5-phenyl-1,4-benzodiazepine series. Unprecedented participation by an imine nitrogen
TL;DR: The previously unknown 3aminomethyl-1,3-dihydro-5-(2′-fluorophenyl)-2H,4-benzodiazepin-2-one, 3a, was synthesized in two steps as a racemate.
Journal ArticleDOI
Development of 1,4-Benzodiazepine Cholecystokinin Type B Antagonists.
Mark G. Bock,Robert M. DiPardo,B. E. Evans,Kenneth E. Rittle,W. L. Whitter,V. M. Garsky,Kevin F. Gilbert,James L. Leighton,K. L. Carson,E. C. Mellin,D. F. Veber,R. S. L. Chang,Victor J. Lotti,Stephen B. Freedman,A. J. Smith,Shil Patel,P. S. Anderson,Roger M. Freidinger +17 more